MYRIAD GENETICS INC MYGN
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
5/9
Piotroski F — financial health
-5.88
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $824.5M | -$365.9M | $576.6M | — | $368.0M |
| 2024 | $837.6M | -$127.3M | $585.4M | — | $701.1M |
| 2023 | $753.2M | -$263.3M | $517.0M | — | $783.2M |
| 2022 | $678.4M | -$112.0M | $476.4M | — | $885.8M |
| 2021 | $690.6M | -$27.2M | — | — | $967.8M |
| 2020 | $557.1M | -$223.6M | — | — | $881.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Raha Samraat S. | President and CEO | 2026-06-11 | Grant | 3,542 | $3.94 |
| Donnelly Brian J | Chief Commerical Officer | 2026-06-11 | Grant | 5,000 | $3.94 |
| Kumar Rashmi | director | 2026-06-08 | Sell | 15,000 | $4.46 |
| Skovronsky Daniel | director | 2026-06-04 | Grant | 59,701 | — |
| Newcomer Lee Nisley | director | 2026-06-04 | Grant | 59,701 | — |
| Davis Mark Steven | director | 2026-06-04 | Grant | 59,701 | — |
| Phanstiel S. Louise | director | 2026-06-04 | Grant | 59,701 | — |
| Dreismann Heinrich | director | 2026-06-04 | Grant | 59,701 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.88 (distress)
- Working capital / assets 0.281
- Retained earnings / assets -1.589
- EBIT / assets -0.548
- Equity / liabilities 1.087
Source: SEC EDGAR filings · CIK 0000899923 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.